The annual budget that a patient with diabetes must follow in Peru to treat their disease can be very varied, however some studies argue that this figure is around US $ 300 per year on average, said Edwin Castro, general manager of Novo Nordisk, Danish signing leader in the prevention and treatment of diabetes.
"But that (the budget) depends greatA GESTION.pe.
"But a person who is not well controlled and who begins to present complications can raise this figure exponentially," he noted.
The specialist pointed out that it should be taken into account that patients who require renal dialysis and people suffering from amputations are mostly diabetic patients who have not been controlled on time;So the cost of treatment is "obviously incalculable."
Novo Nordisk has more than two years of operations in Peru and has 10% Peruvian market share with its modern insulin portfolio.Recently, Novo Nordisk and Peruvian University Cayetano Heredia signed a scientific cooperation agreement.
Castro mentioned that diabetes cases in Peru are more likely in the economically active population (PEA), since these people can enter a pre-diabetes state and then diabetes, since they are people whose lifestyles have changedand usually consume foods that are harmful to health as the so -called "Fast Food."
"The most dangerous thing is that a large number of child/youth population is also included, which do not exercise and feed very badly, since they, in the future, are strong candidates to suffer from diabetes," he noted.
He said that the cases are mostly presented in the cities of the coast, having Lima as, perhaps, the one with the highest incidence.
“In the north there is also a high incidence of diabetes especially in Piura.In fact, the urban population is more prone to diabetes, the incidence in the rural areas of the Sierra being less, ”he explained.
He also said that until a few years ago, it was said that the incidence of diabetes in Peru was one of the lowest but today is very close to the Latin American average with an approximate incidence of 6% of the adult population.
He also estimated that a year moves approximately US $ 10 million in the insulin market, both in the public and private sectors.
"When we talk about modern or latest insulins, we could say that thanks to the competition generated in recent years, especially for the entry of Novo Nordisk to the market, these prices have not risen and in some cases some decrease has been seen,", he said.
Although he affirmed that when it comes to human insulins, or previous generation, which are mostly marketed in public institutions, they have reduced their price thanks also to a more open market.
"In Peru, the official patient figure is 1,140,000 people, however specialists consider that the real number could be close to two million and by 2030 it is estimated that this number could be close to three million", project.